Evidence map›Paper›PMID 35923807›Full record

ArticleEuropean heart journal open2021

Feasibility and safety of cangrelor in patients with suboptimal P2Y

Abi Selvarajah, Annerieke H Tavenier, Wilbert L Bor, Vital Houben, Saman Rasoul, Eliza Kaplan, Koen Teeuwen, Sjoerd H Hofma, Erik Lipsic, Giovanni Amoroso and 4 more

Abstract read
In one paragraph

Article in European heart journal open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII Registry.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Observational
  2. Antiplatelet strategy during ad-hoc percutaneous coronary intervention in elective patients: how aggressive should we be?Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Abi SelvarajahDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.ORCID https://orcid.org/0000-0002-2291-6808
Annerieke H TavenierDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
Wilbert L BorDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Vital HoubenDepartment of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands.
Saman RasoulDepartment of Cardiology, Zuyderland Medical Center, Heerlen, The Netherlands.
Eliza KaplanDepartment of Cardiology, Venlo VieCuri Medical Center, Venlo, The Netherlands.
Koen TeeuwenDepartment of Cardiology, Catharina Hospital, Eindhoven, The Netherlands.
Sjoerd H HofmaDepartment of Cardiology, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Erik LipsicDepartment of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Giovanni AmorosoDepartment of Cardiology, OLVG Hospital, Amsterdam, The Netherlands.
Maarten A H van LeeuwenDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
Jur M Ten BergDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
Arnoud W J van 't HofDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.
Renicus S HermanidesDepartment of Cardiology, Isala Hospital, Zwolle, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CangrelorP2Y12 inhibitorsPercutaneous coronary interventionPlatelet inhibition

Identifiers

PMID35923807
PMCPMC9242080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.